Skip to content
Trial Eligibility
Menu

Prostate Cancer Clinical Trials near Nashville, TN

Illustration: An older man fishing from a wooden dock on a calm lake at dawn
Illustration of Nashville, TN

56 studies for Prostate Cancer are recruiting at 78 sites within 50 miles of Nashville, Tennessee, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Prostate Cancer trials in the US or all trials near Nashville.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Prostate Cancer studies enrolling near Nashville

Showing the 50 nearest of 56 studies.
  1. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

    NCT07028853

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest sites: Tennessee Oncology, PLLC - Investigational Drug Services (Nashville, TN); Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  2. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    NCT03460977

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute - Pharmacy (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  3. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    NCT04557449

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Sarah Cannon Research Institute - Pharmacy (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  4. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    NCT05919264

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (Nashville, TN); Vanderbilt Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  5. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    NCT06778863

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sarah Cannon Research Institute (SCRI) Oncology Partners (Nashville, TN); Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  6. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    NCT06784193

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  7. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    NCT06800313

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Male

    Nearest sites: Sarah Cannon Research Institute (Nashville, TN); Urology Associates (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  8. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    NCT06925737

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest sites: Henry-Joyce Cancer Clinic ( Site 0042) (Nashville, TN); SCRI Oncology Partners ( Site 0074) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  9. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

    NCT07213674

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest sites: Sarah Cannon Research Institute Oncology Partners (Nashville, TN); United States Oncology Regulatory Affairs Corporate Office (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  10. A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    NCT07365995

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest sites: SCRI Oncology Partners (Nashville, TN); Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  11. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest site: Massive Bio SYNERGY-AI site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  12. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  13. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    NCT03866382

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  14. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    NCT04221542

    • Phase 1
    • Ages 18 years and older
    • Sex: Male

    Nearest site: United States Oncology Regulatory Affairs Corporate Office (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  15. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    NCT04503265

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  16. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  17. Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    NCT04606446

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  18. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    NCT04729114

    • Phase 1
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Urology Associates PC (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  19. ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

    NCT04986423

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Urology Associates, P.C. (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  20. High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

    NCT05011383

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  21. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    NCT05176483

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Exelixis Clinical Site #3 (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  22. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    NCT05489211

    • Phase 2
    • Ages 18 to 130 years
    • Sex: All

    Nearest site: Research Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  23. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    NCT05519449

    • Phase 1
    • Ages 18 to 100 years
    • Sex: Male

    Nearest site: Sarah Cannon Research (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  24. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    NCT05914116

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Research Site 136 (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  25. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

    NCT05932862

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Exelixis Clinical Site #6 (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  26. An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

    NCT05939414

    • Phase 3
    • Ages 18 to 100 years
    • Sex: Male

    Nearest site: Vanderbilt University Medical Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  27. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    NCT05983432

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon - Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

    NCT06056830

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Urology Associates of Nashville (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    NCT06095089

    • Phase 1
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Tennessee Oncology (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

    NCT06134232

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Urology Associates of Nashville (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    NCT06136624

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners ( Site 7000) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    NCT06172478

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    NCT06239194

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    NCT06440005

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    NCT06465069

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    NCT06545942

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Investigative Site #102 (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

    NCT06592924

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Vanderbilt University/Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    NCT06842498

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Henry-Joyce Cancer Clinic (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

    NCT06952803

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Research Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

    NCT06966024

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Vanderbilt- Ingram Cancer Center (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

    NCT06990880

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: GSK Investigational Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

    NCT07005154

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Tennessee Oncology Nashville (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. DESTINY-PANTUMOUR04

    NCT07124000

    • Observational
    • Ages 18 to 130 years
    • Sex: All

    Nearest site: Research Site (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

    NCT07140900

    • Phase 1
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Sarah Cannon Research Institute (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    NCT07164443

    • Phase 3
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Tennessee Oncology Nashville (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

    NCT07181473

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (SCRI) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    NCT07288359

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Tennessee Oncology PLLC (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

    NCT07488923

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sarah Cannon Research Institute (SCRI) (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

    NCT07493512

    • Phase 1
    • Ages 18 years and older
    • Sex: Male

    Nearest site: Sarah Cannon Research Institute Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    NCT07503808

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: SCRI Oncology Partners (Nashville, TN)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Prostate Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.